Alpha 2.0
Login Register
» Articles » PMID: 21388446

Liraglutide Therapy in Prader-Willi Syndrome

Overview
Journal Diabet Med
Specialty Endocrinology
Date 2011 Mar 11
PMID 21388446
Citations 7
Authors
K Cyganek
T Koblik
E Kozek
M Wojcik
J Starzyk
M T Malecki
Affiliations
Soon will be listed here.
Citing Articles

Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report.

Dinoi E, Daniele G, Michelucci A, Baldinotti F, Campi F, Marchetti P Front Endocrinol (Lausanne). 2025; 16:1533209.

PMID: 39996062 PMC: 11847660. DOI: 10.3389/fendo.2025.1533209.

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review.

Koceva A, Mlekus Kozamernik K, Janez A, Herman R, Ferjan S, Jensterle M Front Endocrinol (Lausanne). 2025; 15:1528457.

PMID: 39906041 PMC: 11790462. DOI: 10.3389/fendo.2024.1528457.

Intensive management of obesity in people with Prader-Willi syndrome.

Nolan B, Proietto J, Sumithran P Endocrine. 2022; 77(1):57-62.

PMID: 35524875 PMC: 9242929. DOI: 10.1007/s12020-022-03064-1.

Anti-Obesity Medication Use in Children and Adolescents with Prader-Willi Syndrome: Case Review and Literature Search.

Goldman V, Naguib M, Vidmar A J Clin Med. 2021; 10(19).

PMID: 34640558 PMC: 8509766. DOI: 10.3390/jcm10194540.

Case Report: Liraglutide for Weight Management in Beckwith-Wiedemann Syndromic Obesity.

Caputo M, Daffara T, Bellone S, Mancioppi V, Marzullo P, Aimaretti G Front Endocrinol (Lausanne). 2021; 12:687918.

PMID: 34239499 PMC: 8258411. DOI: 10.3389/fendo.2021.687918.